Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, open-label and randomized trial for evaluation of the
effect of a 5-day administration of high doses of spironolactone (≥100mg daily) on diuresis,
natriuresis, weight loss and levels of NT-proBNP in hospitalized patients with acute
decompensated heart failure (ADHF). Mineralocorticoid receptor antagonists (MRAs) are
recommended as standard of care (SOC) in management of heart failure (HF) patients. However,
recommended doses of MRAs (up to 50mg daily) have any impact on signs and symptoms of volume
overload. Therefore, the proposed study will aim to show the impact of high doses of
spironolactone to improve diuresis, natriuresis, weight loss and levels of NT-proBNP in
hospitalized patients with ADHF.